Novo Nordisk A/S (NONOF)
144.14
+1.81
(+1.27%)
USD |
OTCM |
Mar 21, 15:55
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 324.36B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 28.92% |
| Valuation | |
| PE Ratio | 41.62 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 13.08 |
| Price to Book Value | 26.99 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.5896 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2546 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.40% |
News
Headline
Wire
Time (ET)
SA Breaking News
01/01 14:00
SA Breaking News
06/06 14:31
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/10/2023 | -- | Earnings Call | Q2 2023 | -- | -- | -- | |
| 05/04/2023 | -- | Results | Q1 2023 | -- | -- | -- | |
| 11/02/2022 | -- | Results | Q3 2022 | -- | -- | -- | |
| 11/02/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -- | -- | -- | |
| 02/02/2022 | 07:00 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 02/02/2022 | -- | Results | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | May. 04, 2023 |
| Last Earnings Release | Nov. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 12, 2022 |
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 1.616 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.2954 |
| Yield to Sector | 0.1964 |
| Yield to Industry | 0.2972 |
| Last Dividend Amt. | 0.5896 |
| Dividend Frequency | Semi-Annually |
| Last Ex-Dividend Date | Aug. 12, 2022 |
| Yield (TTM) | 0.41% |
| Forward Yield | 1.12% |
| Payout Ratio | 45.58% |
| Cash Payout Ratio | 39.45% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 20, 2023.
Fundamentals
| Revenue (TTM) | 25.03B |
| Total Expenses (TTM) | 14.43B |
| Net Income (TTM) | 7.869B |
| Total Assets (Quarterly) | 34.72B |
| Total Liabilities (Quarterly) | 22.71B |
| Shareholders Equity (Quarterly) | 12.02B |
| Cash from Operations (TTM) | 11.18B |
| Cash from Investing (TTM) | -3.532B |
| Cash from Financing (TTM) | -7.343B |
Ratings
Profile
Edit
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | May. 04, 2023 |
| Last Earnings Release | Nov. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 12, 2022 |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| MRSJX | 483.99M DKK | 3.13% |
| VEURX | 450.39M DKK | 2.00% |
| VGK | 450.39M DKK | 2.00% |
| EFA | 722.46M DKK | 1.57% |
| FSPSX | 576.36M DKK | 1.44% |
| IEFA | 1.222B DKK | 1.34% |
| VDVIX | 1.686B DKK | 1.06% |
| VEA | 1.686B DKK | 1.06% |
| VFWPX | 449.26M DKK | 0.93% |
| VEU | 449.26M DKK | 0.93% |
| VTISX | 2.911B DKK | 0.80% |
| VXUS | 2.911B DKK | 0.80% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NONOF Tweets |